Adoption of EMA Trial Transparency Policy Postponed Until October

Clinical Trials Advisor
A A
The European Medicines Agency’s management board has delayed formal adoption of a controversial clinical trial transparency policy, pending further clarifications on final wording and practical considerations at its Oct. 2 meeting.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00